Landos Biopharma, Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted from Q2 2020 to Q1 2024

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Landos Biopharma, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q2 2020 to Q1 2024.
  • Landos Biopharma, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending March 31, 2024 was 6.21M shares, a 4.27% decline year-over-year.
  • Landos Biopharma, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 6.28M shares, a 55.9% increase from 2022.
  • Landos Biopharma, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 4.03M shares, a 89.3% decline from 2021.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 6.21M -277K -4.27% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 6.28M +2.25M +55.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 6.21M +2.18M +54.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 6.21M +2.18M +54.2% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-09
Q1 2023 6.48M -33.8M -83.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 4.03M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 4.03M -35.9M -89.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 4.03M -30.4M -88.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 40.3M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q3 2021 40M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 34.4M +22.3M +185% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q2 2020 12.1M Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.